Q: Based on your previous comments on Pliant Therapeutics could you please give an opinion on recent earnings and going forward what do you see for the stock and the market they are in. Can you also comment on management and insider ownership if they are worthy enough points to even discuss.
Thank you.
Thank you.
Q: Based on your previous comments on Pliant Therapeutics could you please give an opinion on recent earnings and looking forward for the stock and the market they serve. Thank you
Q: Based on your last comments on Pliant therapeutics(PLRX) from May 12, could you please update on those specific comments and on the recent news that made the stock double. Where do you see it going from here? This is what you wrote last time…
Asked by James on May 12, 2021
5I RESEARCH ANSWER:
PLRX has $277M in cash, but only expected revenue of $16M this year. Cash burn was $37M in 2020. 1Q loss of 64 cents per share was 6% worse than estimates; sales of $2.2M were 49% worse than expected. Insiders own 3.5% directly. We do not know management but see no concerns there. There is not much to go on here. As a clinical stage company, performance is going to depend on trial results. It has two main trials (early stage) that will be releasing results later this year. The pipeline is decent but again, early stage. It has been public less than a year, but shares have nearly doubled in that time. There is upside potential for sure, but the future may also be binary based on good/bad trial results.
Asked by James on May 12, 2021
5I RESEARCH ANSWER:
PLRX has $277M in cash, but only expected revenue of $16M this year. Cash burn was $37M in 2020. 1Q loss of 64 cents per share was 6% worse than estimates; sales of $2.2M were 49% worse than expected. Insiders own 3.5% directly. We do not know management but see no concerns there. There is not much to go on here. As a clinical stage company, performance is going to depend on trial results. It has two main trials (early stage) that will be releasing results later this year. The pipeline is decent but again, early stage. It has been public less than a year, but shares have nearly doubled in that time. There is upside potential for sure, but the future may also be binary based on good/bad trial results.